Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34986285

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2022 Jan 6
First author
Tawbi HA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 Jan 6;386(1):91-92. doi: 10.1056/NEJMe2116892.
    note
    Source null
    related pmid
    34986291
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Mar;19(3):149. doi: 10.1038/s41571-022-00602-8.
    note
    Source null
    related pmid
    35031714
    relationship
    Comment in
  3. citation
    N Engl J Med. 2022 Apr 28;386(17):1668-1669. doi: 10.1056/NEJMc2119768.
    note
    Source null
    related pmid
    35476655
    relationship
    Comment in
  4. citation
    N Engl J Med. 2022 May 12;386(19):1860. doi: 10.1056/NEJMc2201558.
    note
    Source null
    related pmid
    35544393
    relationship
    Comment in
  5. citation
    Cell. 2022 Dec 22;185(26):4866-4869. doi: 10.1016/j.cell.2022.12.003.
    note
    Source null
    related pmid
    36563660
    relationship
    Comment in

Authors and identifiers

  1. name
    Tawbi HA
    type
    Author
  2. name
    Schadendorf D
    type
    Author
  3. name
    Lipson EJ
    type
    Author
  4. name
    Ascierto PA
    type
    Author
  5. name
    Matamala L
    type
    Author
  6. name
    Castillo Gutiérrez E
    type
    Author
  7. name
    Rutkowski P
    type
    Author
  8. name
    Gogas HJ
    type
    Author
  9. name
    Lao CD
    type
    Author
  10. name
    De Menezes JJ
    type
    Author
  11. name
    Dalle S
    type
    Author
  12. name
    Arance A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Tawbi HA
    type
    Author
  2. name
    Schadendorf D
    type
    Author
  3. name
    Lipson EJ
    type
    Author
  4. name
    Ascierto PA
    type
    Author
  5. name
    Matamala L
    type
    Author
  6. name
    Castillo Gutiérrez E
    type
    Author
  7. name
    Rutkowski P
    type
    Author
  8. name
    Gogas HJ
    type
    Author
  9. name
    Lao CD
    type
    Author
  10. name
    De Menezes JJ
    type
    Author
  11. name
    Dalle S
    type
    Author
  12. name
    Arance A
    type
    Author
bibliography ids
  1. nci-bib-009391db95e63e1266aba212
book metadata
content sha256
eecf38e6cfa37269d22412a8513b8fe908acb5108ca4aab4d66deb2f6de93505
document type
citation
dois
  1. 10.1056/NEJMoa2109970
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:34986285
immutable id
pubmed:34986285@eecf38e6cfa37269d22412a8513b8fe908acb5108ca4aab4d66deb2f6de93505
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
1
name
The New England journal of medicine
nlm unique id
0255562
pages
24-34
volume
386
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 Jan 6;386(1):91-92. doi: 10.1056/NEJMe2116892.
    note
    Source null
    related pmid
    34986291
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Mar;19(3):149. doi: 10.1038/s41571-022-00602-8.
    note
    Source null
    related pmid
    35031714
    relationship
    Comment in
  3. citation
    N Engl J Med. 2022 Apr 28;386(17):1668-1669. doi: 10.1056/NEJMc2119768.
    note
    Source null
    related pmid
    35476655
    relationship
    Comment in
  4. citation
    N Engl J Med. 2022 May 12;386(19):1860. doi: 10.1056/NEJMc2201558.
    note
    Source null
    related pmid
    35544393
    relationship
    Comment in
  5. citation
    Cell. 2022 Dec 22;185(26):4866-4869. doi: 10.1016/j.cell.2022.12.003.
    note
    Source null
    related pmid
    36563660
    relationship
    Comment in
outcomes validated
false
pmid
34986285
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
de290d8bc9dd37d068aeb038cf6fcfdd0bcd253cc9b426ee0c538a5a6198ba2a
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Jan 6
precision
day
year
2022
publication types
  1. Clinical Trial, Phase II
  2. Clinical Trial, Phase III
  3. Comparative Study
  4. Journal Article
  5. Multicenter Study
  6. Randomized Controlled Trial
  7. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34986285/
title
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

Preserved source evidence · Not medical advice